← Eichor
Condition: Advanced Triple Negative Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Triple Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Nega
Phase 2 · 2 location(s) · Fudan University · NCT06636981a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 16 location(s) · Tubulis GmbH · NCT06657222Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Phase 2 · 1 location(s) · QIAO LI · NCT06955156Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Phase 2 · 5 location(s) · European Institute of Oncology · NCT06690840This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06649331Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Phase 2 · 1 location(s) · Fudan University · NCT06889610A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05019690Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chem
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06771609A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult
Phase 1/Phase 2 · 61 location(s) · Bristol-Myers Squibb · NCT06618287A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
Phase 2 · 2 location(s) · BeBetter Med Inc · NCT06685796A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Phase 1/Phase 2 · 4 location(s) · Fundacio Clinic Barcelona · NCT05451784BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 · 17 location(s) · SillaJen, Inc. · NCT05768932
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.